<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:56:25Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10521779" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10521779</identifier>
        <datestamp>2023-09-27</datestamp>
        <setSpec>lwwopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Hepatology</journal-id>
              <journal-id journal-id-type="iso-abbrev">Hepatology</journal-id>
              <journal-id journal-id-type="publisher-id">HEP</journal-id>
              <journal-title-group>
                <journal-title>Hepatology (Baltimore, Md.)</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0270-9139</issn>
              <issn pub-type="epub">1527-3350</issn>
              <publisher>
                <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
                <publisher-loc>Hagerstown, MD</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10521779</article-id>
              <article-id pub-id-type="pmcid">PMC10521779</article-id>
              <article-id pub-id-type="pmc-uid">10521779</article-id>
              <article-id pub-id-type="pmid">37080558</article-id>
              <article-id pub-id-type="pmid">37080558</article-id>
              <article-id pub-id-type="publisher-id">HEP-22-2191</article-id>
              <article-id pub-id-type="doi">10.1097/HEP.0000000000000417</article-id>
              <article-id pub-id-type="art-access-id">00023</article-id>
              <article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Articles: Steatohepatitis</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4889-0714</contrib-id>
                  <name>
                    <surname>Li</surname>
                    <given-names>Jiahui</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <email>li.jiahui@mayo.edu</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lu</surname>
                    <given-names>Xin</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff2" ref-type="aff">2</xref>
                  <email>Lu.Xin@mayo.edu</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zhu</surname>
                    <given-names>Zheng</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <email>dr_zhuzheng@hotmail.com</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kalutkiewicz</surname>
                    <given-names>Kyle J.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <email>Kalutkiewicz.Kyle@mayo.edu</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mounajjed</surname>
                    <given-names>Taofic</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <email>Mounajjed.Taofic@mayo.edu</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Therneau</surname>
                    <given-names>Terry M.</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7514-1030</contrib-id>
                  <name>
                    <surname>Venkatesh</surname>
                    <given-names>Sudhakar K.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <email>venkatesh.sudhakar@mayo.edu</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sui</surname>
                    <given-names>Yi</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <email>Sui.Yi@mayo.edu</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Glaser</surname>
                    <given-names>Kevin J.</given-names>
                  </name>
                  <email>glaser.kevin@mayo.edu</email>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hoodeshenas</surname>
                    <given-names>Safa</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <email>hoodeshenas.safa@mayo.edu</email>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9411-5671</contrib-id>
                  <name>
                    <surname>Manduca</surname>
                    <given-names>Armando</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <email>manduca.armando@mayo.edu</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shah</surname>
                    <given-names>Vijay H.</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                  <email>shah.vijay@mayo.edu</email>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7041-5074</contrib-id>
                  <name>
                    <surname>Ehman</surname>
                    <given-names>Richard L.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <email>ehman.richard@mayo.edu</email>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8393-8410</contrib-id>
                  <name>
                    <surname>Allen</surname>
                    <given-names>Alina M.</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                  <email>allen.alina@mayo.edu</email>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6778-192X</contrib-id>
                  <name>
                    <surname>Yin</surname>
                    <given-names>Meng</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <email>yin.meng@mayo.edu</email>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label>Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA</aff>
              <aff id="aff2"><label>2</label>Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China</aff>
              <aff id="aff3"><label>3</label>Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota, USA</aff>
              <aff id="aff4"><label>4</label>Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA</aff>
              <aff id="aff5"><label>5</label>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA</aff>
              <author-notes>
                <corresp><bold>Correspondence</bold> Meng Yin, Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, Minnesota 55905, USA. Email: <email>yin.meng@mayo.edu</email> Alina M. Allen, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First St SW, Rochester, Minnesota 55905, USA. Email: <email>allen.alina@mayo.edu</email>
</corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>10</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>1</day>
                <month>5</month>
                <year>2023</year>
              </pub-date>
              <volume>78</volume>
              <issue>4</issue>
              <fpage>1200</fpage>
              <lpage>1208</lpage>
              <history>
                <date date-type="received">
                  <day>28</day>
                  <month>10</month>
                  <year>2022</year>
                </date>
                <date date-type="rev-recd">
                  <day>14</day>
                  <month>3</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>24</day>
                  <month>3</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0</ext-link> (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>
</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="hep-78-1200.pdf"/>
              <abstract>
                <sec>
                  <title>Background and Aims:</title>
                  <p>The presence of at-risk NASH is associated with an increased risk of cirrhosis and complications. Therefore, noninvasive identification of at-risk NASH with an accurate biomarker is a critical need for pharmacologic therapy. We aim to explore the performance of several magnetic resonance (MR)-based imaging parameters in diagnosing at-risk NASH.</p>
                </sec>
                <sec>
                  <title>Approach and Results:</title>
                  <p>This prospective clinical trial (NCT02565446) includes 104 paired MR examinations and liver biopsies performed in patients with suspected or diagnosed NAFLD. Magnetic resonance elastography-assessed liver stiffness (LS), 6-point Dixon-derived proton density fat fraction (PDFF), and single-point saturation-recovery acquisition-calculated T1 relaxation time were explored. Among all predictors, LS showed the significantly highest accuracy in diagnosing at-risk NASH [AUC<sub>LS</sub>: 0.89 (0.82, 0.95), AUC<sub>PDFF</sub>: 0.70 (0.58, 0.81), AUC<sub>T1</sub>: 0.72 (0.61, 0.82), <italic toggle="yes">z</italic>-score test z &gt;1.96 for LS vs any of others]. The optimal cutoff value of LS to identify at-risk NASH patients was 3.3 kPa (sensitivity: 79%, specificity: 82%, negative predictive value: 91%), whereas the optimal cutoff value of T1 was 850 ms (sensitivity: 75%, specificity: 63%, and negative predictive value: 87%). PDFF had the highest performance in diagnosing NASH with any fibrosis stage [AUC<sub>PDFF</sub>: 0.82 (0.72, 0.91), AUC<sub>LS</sub>: 0.73 (0.63, 0.84), AUC<sub>T1</sub>: 0.72 (0.61, 0.83), |z| &lt;1.96 for all].</p>
                </sec>
                <sec>
                  <title>Conclusion:</title>
                  <p>Magnetic resonance elastography-assessed LS alone outperformed PDFF, and T1 in identifying patients with at-risk NASH for therapeutic trials.</p>
                </sec>
              </abstract>
              <abstract abstract-type="graphical">
                <p>
                  <fig position="float" id="GA1">
                    <graphic xlink:href="hep-78-1200-g001" position="float"/>
                  </fig>
                </p>
              </abstract>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>SDC</meta-name>
                  <meta-value>T</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>OPEN-ACCESS</meta-name>
                  <meta-value>TRUE</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>Read-along</meta-name>
                  <meta-value>YES</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro">
              <title>INTRODUCTION</title>
              <p>NAFLD is a worldwide epidemic with increasing prevalence.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> As the progressive form of NAFLD, NASH accounts for the increase in cirrhosis since 1990.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> Fibrosis is the most important predictor of mortality in NAFLD.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> It has been demonstrated that patients with NASH with fibrosis, particularly stage 2 or higher, have less favorable outcomes with a significantly increased risk of liver-related mortality.<sup><xref rid="R4" ref-type="bibr">4</xref>–<xref rid="R7" ref-type="bibr">7</xref></sup> A NASH diagnosis with fibrosis stage 2 or higher (referred to as at-risk NASH) is now used as criteria for enrollment in clinical trials and pharmacologic therapy. Therefore, identifying patients with NASH and at-risk NASH is critically needed in clinical trials and practice.</p>
              <p>Even though liver biopsy is currently the clinical gold standard for diagnosing NASH and fibrosis, noninvasive imaging biomarkers provide accurate quantitative assessments in monitoring disease progression/regression and evaluating therapy responses in a more practical way. Magnetic resonance elastography (MRE)-assessed liver stiffness (LS) has been demonstrated to be the most accurate noninvasive biomarker for staging fibrosis<sup><xref rid="R8" ref-type="bibr">8</xref>–<xref rid="R10" ref-type="bibr">10</xref></sup> and a potential predictor for diagnosing NASH.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> Proton density fat fraction (PDFF) is a reliable biomarker for quantifying hepatic fat content, which is more sensitive and accurate than histopathological steatosis grading from liver biopsy.<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref></sup> A recent meta-analysis assessed the clinical utility of iron-corrected T1 “(cT1)” in identifying patients with at-risk NASH.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> However, histology data derived from multiple centers were not centrally interpreted, which increases the risk of inaccurate NASH diagnosis.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> Therefore, we aimed to perform a single-center head-to-head comparison of the diagnostic performance of MRE-assessed LS, PDFF, and T1, in identifying patients with NASH and at-risk NASH.</p>
            </sec>
            <sec sec-type="methods">
              <title>METHODS</title>
              <sec>
                <title>Study design and participants</title>
                <p>This was a prospective clinical trial (NCT02565446),<sup><xref rid="R16" ref-type="bibr">16</xref></sup> including 89 patients who had suspected or diagnosed NAFLD, without other known chronic liver diseases or any causes of secondary hepatic fat accumulation. All patients underwent MRI/MRE exams and liver biopsies (see the flow chart of patient enrollment in Supplemental Material S1, <ext-link xlink:href="http://links.lww.com/HEP/H132" ext-link-type="uri">http://links.lww.com/HEP/H132</ext-link>). Informed consent in writing was obtained from each patient and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the Mayo Clinic Institutional Review Board.</p>
              </sec>
              <sec>
                <title>MRI and processing</title>
                <p>All MRI/MRE examinations were performed on 1.5T whole-body scanners (GE Healthcare) at Mayo Clinic. All patients were scanned in the supine position after a fasting period of at least 4 hours. The imaging protocol contains MRE imaging (60 Hz gradient-echo 2-dimensional MRE), 6-point Dixon imaging (IDEAL-IQ), and T1 mapping (SMART<sub>1</sub>Map). Imaging parameters are illustrated in Supplemental Table S2, (<ext-link xlink:href="http://links.lww.com/HEP/H132" ext-link-type="uri">http://links.lww.com/HEP/H132</ext-link>).</p>
              </sec>
              <sec>
                <title>Magnetic resonance elastography</title>
                <p>The MRE images were acquired by placing a passive driver against the anterior body wall of patients over the right lobe of the liver. The driver was held in place by an elastic band wrapped around the body. The continuous mechanical waves for MRE were generated by an active driver (Resoundant, Inc.) outside the scanner room, and were delivered to the passive driver through a 7.6 m long plastic tube. The LS measurements were calculated from freehand regions of interest drawn on each slice, which included only liver parenchyma, and avoided large vessels, bile ducts, and regions with an inadequate magnitude of signal or shear wave amplitude (ie, artifacts from cardiac movement and edges). In this study, LS represents the magnitude of the complex shear modulus (|G*|) derived from 2-dimensional MRE data. It was reported as mean and SD as described in the previous study.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> One analyst (Jiahui Li with 5 years of experience) postprocessed all the images while blinded to clinical, laboratory, and histopathological data.</p>
              </sec>
              <sec>
                <title>Proton density fat fraction</title>
                <p>A 6-echo Dixon method was used to acquire the measurement of the hepatic fat fraction. Water and fat images, PDFF, and R2* (1/T2*, the relaxation rates of observable or effective T2) maps were obtained from image reconstruction (IDEAL-IQ, GE Healthcare). The measurements of PDFF and R2* were calculated from regions of interest manually drawn in 9 anatomic segments by 2 analysts (Jiahui Li with 5 years of experience and Xin Lu with 2 years of experience), respectively.</p>
              </sec>
              <sec>
                <title>T1 mapping</title>
                <p>The investigational pulse sequence using single-point, saturation-recovery fast imaging using steady-state acquisition, was performed to measure the native (noncontrast) true T1 relaxation time of liver tissue. One oval-shaped regions of interest was drawn on each slice by 1 analyst (Safa Hoodeshenas, 4 years of experience), to cover as much liver parenchyma as possible, and avoid large vessels, bile ducts, fissures, and fossae. The T1 measurements were calculated as an area-weighted mean value.</p>
              </sec>
              <sec>
                <title>Histologic assessment</title>
                <p>All participants had liver biopsies, and 1 pathologist with expertise in NASH (Taofic Mounajjed, 10 years of experience) reviewed all the specimens while blinded to imaging, clinical and laboratory results. The histologic assessment included the presence of NASH, grade of steatosis, inflammation, ballooning, and fibrosis stage based on NASH Clinical Research Network criteria.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> At-risk NASH was defined as NASH with stage ≥2 fibrosis.</p>
              </sec>
              <sec>
                <title>Statistical analyses</title>
                <p>The nonparametric Dunn multiple comparison tests with Bonferroni adjustment and Wilcoxon rank sum test were applied to test the differences in imaging parameters (LS, PDFF, and T1). Spearman correlations were used to analyze the relationship between imaging biomarkers. The prediction models were generated from 3 predictors, individually or by combinations. Nominal logistic models trained with ridge regularization and iterative leave-one-out cross-validation were used to detect NASH and at-risk NASH. The overall diagnostic accuracies (reported as the AUC) of imaging prediction models were analyzed by concordance analysis using a robust variance estimator— the Huber sandwich estimator—which effectively accounts for the within-subject correlation in 15 patients with follow-up examinations/biopsies. <italic toggle="yes">Z</italic>-score tests were used to compare AUCs.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> Final retraining of each model was performed on the whole data set to estimate the standardized predictor ORs to compare predictor importance. Sensitivity, specificity, positive predictive value, and negative predictive value (NPV) were calculated to assess the predictor performance. A significance level of <italic toggle="yes">p</italic> &lt; 0.05 for group comparisons and correlation analyses, and |z| &gt; 1.96 for performance comparisons were used in this study. All statistical analyses were performed using <italic toggle="yes">R</italic> (survival package, version 4.1.1) and Python (version 3.8.5).</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>RESULTS</title>
              <sec sec-type="subjects">
                <title>Patient characteristics</title>
                <p>In this prospective clinical trial (NCT02565446), we enrolled 89 participants at risk of NAFLD, who underwent a total of 104 MRI/MRE examinations paired with concurrent liver biopsy. The purpose of these procedures was to evaluate the diagnostic accuracy of various imaging parameters in the longitudinal monitoring of NAFLD. Of the 104 MRI/MRE examinations, 89 were performed at baseline/enrollment and 15 examinations were performed after 1-year follow-up. During the time between the two assessments, 2 participants underwent a bariatric operation, whereas the remaining 13 received lifestyle counseling but did not receive any medication treatment. The NAFLD activity score changed in 9 of the 15 patients between the two assessments, thus they were accounted as 2 independent assessments. The median time between MRI/MRE and liver biopsy was 1 day (interquartile range: 1, 7). Among the 104 paired examinations, 45 (43%) were diagnosed with NASH and 28 (27%) were identified as at-risk NASH by histology (example images shown in Figure <xref rid="F1" ref-type="fig">1</xref>). Table <xref rid="T1" ref-type="table">1</xref> represents the participant characteristics.</p>
                <fig position="float" id="F1">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Example images. The first row represents images from a patient with non-NASH (female, 45 y, BMI = 30.2 kg/m<sup>2</sup>): PDFF = 2.1%, LS = 1.69 kPa, T1 = 794 ms. The second row represents images from a patient with NASH (female, 48 y, BMI = 32.8 kg/m<sup>2</sup>): PDFF = 20.4%, LS = 2.43 kPa, T1 = 1004 ms. The third row represents images from a patient with at-risk NASH (male, 60 y, BMI = 27.5 kg/m<sup>2</sup>): PDFF = 10.6%, LS = 3.94 kPa, T1 = 858 ms. The white dotted line illustrates the contour of the liver not the ROI for measurements. Abbreviations: BMI, body mass index; LS, liver stiffness; ROI, regions of interest; PDFF, proton density fat fraction.</p>
                  </caption>
                  <graphic xlink:href="hep-78-1200-g002" position="float"/>
                </fig>
                <table-wrap position="float" id="T1">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Demographic, histologic, and imaging characteristics of participants</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" width="1*" span="1"/>
                    <col align="left" width="1*" span="1"/>
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">Characteristics</th>
                        <th align="center" rowspan="1" colspan="1">Paired examinations (N = 104) in 89 participants; n (%)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="2">General information</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Time interval between MRI/MRE and liver biopsy (d)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">1 (1, 7)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Sex (F)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">64 (62)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Age (y)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">55 (46, 60)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> BMI (kg/m<sup>2</sup>)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">33 (30, 39)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Diabetes (yes)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">48 (46)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="2">Histologic findings</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="2"> Steatosis grade</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  0</td>
                        <td align="char" char="(" rowspan="1" colspan="1">31 (30)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  1</td>
                        <td align="char" char="(" rowspan="1" colspan="1">47 (45)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  2</td>
                        <td align="char" char="(" rowspan="1" colspan="1">22 (21)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  3</td>
                        <td align="char" char="(" rowspan="1" colspan="1">4 (4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="2"> Lobular inflammation grade</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  0</td>
                        <td align="char" char="(" rowspan="1" colspan="1">43 (41)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  1</td>
                        <td align="char" char="(" rowspan="1" colspan="1">57 (55)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  2</td>
                        <td align="char" char="(" rowspan="1" colspan="1">4 (4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="2"> Ballooning grade</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  0</td>
                        <td align="char" char="(" rowspan="1" colspan="1">59 (57)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  1</td>
                        <td align="char" char="(" rowspan="1" colspan="1">32 (31)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  2</td>
                        <td align="char" char="(" rowspan="1" colspan="1">13 (13)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="2"> Fibrosis stage</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  0</td>
                        <td align="char" char="(" rowspan="1" colspan="1">54 (52)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  1</td>
                        <td align="char" char="(" rowspan="1" colspan="1">12 (12)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  2</td>
                        <td align="left" rowspan="1" colspan="1">13 (13)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  3</td>
                        <td align="char" char="(" rowspan="1" colspan="1">11 (11)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  4</td>
                        <td align="char" char="(" rowspan="1" colspan="1">14 (13)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">NASH</td>
                        <td align="char" char="(" rowspan="1" colspan="1">45 (43)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">At-risk NASH</td>
                        <td align="char" char="(" rowspan="1" colspan="1">28 (27)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="2">Imaging findings</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> LS (kPa)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">2.7 (2.1, 3.7)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> PDFF (%)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">10.6 (5.4, 19.7)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> T1 relaxation time (ms)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">843.9 (765.7, 967.3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> R2* (s<sup>−1</sup>)</td>
                        <td align="char" char="(" rowspan="1" colspan="1">37.2 (35.0, 41.3)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn fn-type="other">
                      <p><italic toggle="yes">Note:</italic> Continuous measurements are reported as median (interquartile range). Discrete variables are reported as the number and proportion of subjects with the characteristics of interest. All data were calculated regarding each independent examination with paired imaging and biopsy.</p>
                    </fn>
                    <fn fn-type="abbr">
                      <p>Abbreviations: BMI, body mass index; LS, liver stiffness; MRE, magnetic resonance elastography; PDFF, proton density fat fraction.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec>
                <title>Performance of proton density fat fraction and T1 in diagnosing steatosis and NASH</title>
                <p>As shown in Figure <xref rid="F2" ref-type="fig">2</xref>, both PDFF and T1 showed a significant increase in values as the severity of steatosis increased (Kruskal-Wallis rank sum test, <italic toggle="yes">p</italic> &lt; 0.0001 for both). Patients with NASH had significantly elevated PDFF [18.5% (12.5, 23.2) vs 6.0% (3.5, 11.5), <italic toggle="yes">p</italic> &lt; 0.0001] and T1 [901 ms (818.6, 1016.6) vs 809.4 ms (746.0, 885.7), <italic toggle="yes">p</italic> = 0.0002] when compared with non-NASH patients.</p>
                <fig position="float" id="F2">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>Scatter plots of PDFF and T1 for differentiating steatosis grades and NASH. The black line indicates the median value. *<italic toggle="yes">p</italic> &lt; 0.05; **<italic toggle="yes">p</italic> &lt; 0.01; ***<italic toggle="yes">p</italic> &lt; 0.0001. Abbreviation: PDFF, proton density fat fraction.</p>
                  </caption>
                  <graphic xlink:href="hep-78-1200-g003" position="float"/>
                </fig>
              </sec>
              <sec>
                <title>Performance of liver stiffness and T1 in diagnosing fibrosis and at-risk NASH</title>
                <p>Both LS and T1 values were higher in patients with clinically significant fibrosis (stage ≥2) [LS: 4.1 kPa (3.4, 6.1) vs 2.3 kPa (2.0, 2.6), <italic toggle="yes">p</italic> &lt; 0.0001; T1: 890.6 ms (808.1, 995.1) vs 821.3 ms (745.0, 924.6), <italic toggle="yes">p</italic> = 0.008], and at-risk NASH [LS: 3.9 kPa (3.3, 6.1) vs 2.4 kPa (2.1, 2.8), <italic toggle="yes">p</italic> &lt; 0.0001; T1: 925.1 ms (847.2, 1019.7) vs 817.9 ms (746.5, 927.0), <italic toggle="yes">p</italic> = 0.0008] (Figure <xref rid="F3" ref-type="fig">3</xref>).</p>
                <fig position="float" id="F3">
                  <label>FIGURE 3</label>
                  <caption>
                    <p>Scatter plots of LS and T1 for differentiating clinically significant fibrosis (≥stage 2) and at-risk NASH. The black line indicates the median value. *<italic toggle="yes">p</italic> &lt; 0.05; **<italic toggle="yes">p</italic> &lt; 0.01; ***<italic toggle="yes">p</italic> &lt; 0.0001. Abbreviation: LS, liver stiffness.</p>
                  </caption>
                  <graphic xlink:href="hep-78-1200-g004" position="float"/>
                </fig>
                <p>T1 significantly correlated with PDFF (<italic toggle="yes">R</italic> = 0.62, <italic toggle="yes">p</italic> &lt; 0.01), whereas LS did not show any correlation with PDFF (<italic toggle="yes">R</italic> = 0.03, <italic toggle="yes">p</italic> = 0.77) (Figure <xref rid="F4" ref-type="fig">4</xref>).</p>
                <fig position="float" id="F4">
                  <label>FIGURE 4</label>
                  <caption>
                    <p>Correlations between PDFF and T1/LS. **<italic toggle="yes">p</italic> &lt; 0.01. Abbreviations: LS, liver stiffness; PDFF, proton density fat fraction.</p>
                  </caption>
                  <graphic xlink:href="hep-78-1200-g005" position="float"/>
                </fig>
              </sec>
              <sec sec-type="subjects">
                <title>Diagnostic accuracy in identifying patients with NASH and at-risk NASH</title>
                <p>We evaluated the diagnostic performance of several logistic regression models with imaging predictors in identifying patients with NASH and at-risk NASH (Figure <xref rid="F5" ref-type="fig">5</xref>). The multivariate model of PDFF + LS + T1 showed the highest AUC value (0.83, 95% CI: 0.75, 0.92) in diagnosing NASH. The univariable model of LS showed the highest AUC value (0.89, 95% CI: 0.82, 0.95) in diagnosing at-risk NASH.</p>
                <fig position="float" id="F5">
                  <label>FIGURE 5</label>
                  <caption>
                    <p>Summary of AUC for nominal logistic models for distinguishing NASH and at-risk NASH. *<italic toggle="yes">z</italic> &gt; 1.96 when compared with LS in diagnosing at-risk NASH. Abbreviations: LS, liver stiffness; PDFF, proton density fat fraction.</p>
                  </caption>
                  <graphic xlink:href="hep-78-1200-g006" position="float"/>
                </fig>
                <p>PDFF showed the most significant effect (ie, highest standardized ORs) in all univariable and multivariable models for diagnosing patients with NASH. Similarly, LS showed the most significant impact in diagnosing patients with at-risk NASH (Table <xref rid="T2" ref-type="table">2</xref>).</p>
                <table-wrap position="float" id="T2">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Univariate and multivariate prediction models in diagnosing NASH and at-risk NASH</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" width="1*" span="1"/>
                    <col align="left" width="1*" span="1"/>
                    <col align="left" width="1*" span="1"/>
                    <col align="left" width="1*" span="1"/>
                    <col align="left" width="1*" span="1"/>
                    <col align="left" width="1*" span="1"/>
                    <col align="left" width="1*" span="1"/>
                    <col align="left" width="1*" span="1"/>
                    <col align="left" width="1*" span="1"/>
                    <col align="left" width="1*" span="1"/>
                    <col align="left" width="1*" span="1"/>
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">Predictors</th>
                        <th align="center" rowspan="1" colspan="2" axis="1">Univariate</th>
                        <th align="center" rowspan="1" colspan="2" axis="1">PDFF + LS</th>
                        <th align="center" rowspan="1" colspan="2" axis="1">PDFF + T1</th>
                        <th align="center" rowspan="1" colspan="2" axis="1">LS + T1</th>
                        <th align="center" rowspan="1" colspan="2" axis="1">PDFF + LS + T1</th>
                      </tr>
                      <tr>
                        <th align="left" rowspan="1" colspan="1"/>
                        <th align="center" rowspan="1" colspan="1">Coefficient</th>
                        <th align="center" rowspan="1" colspan="1">OR</th>
                        <th align="center" rowspan="1" colspan="1">Coefficient</th>
                        <th align="center" rowspan="1" colspan="1">OR</th>
                        <th align="center" rowspan="1" colspan="1">Coefficient</th>
                        <th align="center" rowspan="1" colspan="1">OR</th>
                        <th align="center" rowspan="1" colspan="1">Coefficient</th>
                        <th align="center" rowspan="1" colspan="1">OR</th>
                        <th align="center" rowspan="1" colspan="1">Coefficient</th>
                        <th align="center" rowspan="1" colspan="1">OR</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="11">NASH</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> PDFF</td>
                        <td align="center" rowspan="1" colspan="1">0.08</td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>1.97</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">0.15</td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>3.98</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">0.08</td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>2.05</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">—</td>
                        <td align="center" rowspan="1" colspan="1">—</td>
                        <td align="center" rowspan="1" colspan="1">0.20</td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>6.02</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> LS</td>
                        <td align="center" rowspan="1" colspan="1">0.33</td>
                        <td align="center" rowspan="1" colspan="1">1.86</td>
                        <td align="center" rowspan="1" colspan="1">0.44</td>
                        <td align="center" rowspan="1" colspan="1">2.28</td>
                        <td align="center" rowspan="1" colspan="1">—</td>
                        <td align="center" rowspan="1" colspan="1">—</td>
                        <td align="center" rowspan="1" colspan="1">0.27</td>
                        <td align="center" rowspan="1" colspan="1">1.67</td>
                        <td align="center" rowspan="1" colspan="1">0.45</td>
                        <td align="center" rowspan="1" colspan="1">2.35</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> T1</td>
                        <td align="center" rowspan="1" colspan="1">0.00</td>
                        <td align="center" rowspan="1" colspan="1">1.88</td>
                        <td align="center" rowspan="1" colspan="1">—</td>
                        <td align="center" rowspan="1" colspan="1">—</td>
                        <td align="center" rowspan="1" colspan="1">0.00</td>
                        <td align="center" rowspan="1" colspan="1">0.86</td>
                        <td align="center" rowspan="1" colspan="1">0.00</td>
                        <td align="center" rowspan="1" colspan="1">1.14</td>
                        <td align="center" rowspan="1" colspan="1">0.00</td>
                        <td align="center" rowspan="1" colspan="1">0.54</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="11">At-risk NASH</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> PDFF</td>
                        <td align="center" rowspan="1" colspan="1">0.04</td>
                        <td align="center" rowspan="1" colspan="1">1.47</td>
                        <td align="center" rowspan="1" colspan="1">0.06</td>
                        <td align="center" rowspan="1" colspan="1">1.71</td>
                        <td align="center" rowspan="1" colspan="1">0.05</td>
                        <td align="center" rowspan="1" colspan="1">1.51</td>
                        <td align="center" rowspan="1" colspan="1">—</td>
                        <td align="center" rowspan="1" colspan="1">—</td>
                        <td align="center" rowspan="1" colspan="1">0.11</td>
                        <td align="center" rowspan="1" colspan="1">2.65</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> LS</td>
                        <td align="center" rowspan="1" colspan="1">0.87</td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>5.25</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">0.55</td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>2.85</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">—</td>
                        <td align="center" rowspan="1" colspan="1">—</td>
                        <td align="center" rowspan="1" colspan="1">0.87</td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>5.21</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">0.92</td>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>5.75</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> T1</td>
                        <td align="center" rowspan="1" colspan="1">0.01</td>
                        <td align="center" rowspan="1" colspan="1">2.13</td>
                        <td align="center" rowspan="1" colspan="1">—</td>
                        <td align="center" rowspan="1" colspan="1">—</td>
                        <td align="center" rowspan="1" colspan="1">0.00</td>
                        <td align="center" rowspan="1" colspan="1">1.48</td>
                        <td align="center" rowspan="1" colspan="1">0.00</td>
                        <td align="center" rowspan="1" colspan="1">1.60</td>
                        <td align="center" rowspan="1" colspan="1">0.00</td>
                        <td align="center" rowspan="1" colspan="1">0.82</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn fn-type="abbr">
                      <p>Abbreviations: LS, liver stiffness; PDFF, proton density fat fraction.</p>
                    </fn>
                    <fn fn-type="other">
                      <p>Bold values indicate highest standardized ORs.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>The optimal cutoff value of LS to identify patients with at-risk NASH was 3.3 kPa, with a sensitivity of 79%, a specificity of 82%, and an NPV of 91%. The optimal cutoff value of T1 was 850 ms, with a sensitivity of 75%, a specificity of 63%, and an NPV of 87% (Table <xref rid="T3" ref-type="table">3</xref>).</p>
                <table-wrap position="float" id="T3">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Diagnostic accuracy of LS and T1 to diagnose patients with at-risk NASH at prespecified thresholds</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" width="1*" span="1"/>
                    <col align="left" width="1*" span="1"/>
                    <col align="left" width="1*" span="1"/>
                    <col align="left" width="1*" span="1"/>
                    <col align="left" width="1*" span="1"/>
                    <col align="left" width="1*" span="1"/>
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">AUC</th>
                        <th align="center" rowspan="1" colspan="1">Threshold</th>
                        <th align="center" rowspan="1" colspan="1">Sensitivity (%)</th>
                        <th align="center" rowspan="1" colspan="1">Specificity (%)</th>
                        <th align="center" rowspan="1" colspan="1">NPV (%)</th>
                        <th align="center" rowspan="1" colspan="1">PPV (%)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LS; 0.89 (95% CI: 0.82-0.95) (kPa)</td>
                        <td align="center" rowspan="1" colspan="1">≥2.9</td>
                        <td align="char" char="." rowspan="1" colspan="1">96</td>
                        <td align="char" char="." rowspan="1" colspan="1">79</td>
                        <td align="char" char="." rowspan="1" colspan="1">98</td>
                        <td align="char" char="." rowspan="1" colspan="1">63</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">≥3.1</td>
                        <td align="char" char="." rowspan="1" colspan="1">89</td>
                        <td align="char" char="." rowspan="1" colspan="1">80</td>
                        <td align="char" char="." rowspan="1" colspan="1">95</td>
                        <td align="char" char="." rowspan="1" colspan="1">63</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">≥3.3</td>
                        <td align="char" char="." rowspan="1" colspan="1">79</td>
                        <td align="char" char="." rowspan="1" colspan="1">82</td>
                        <td align="char" char="." rowspan="1" colspan="1">91</td>
                        <td align="char" char="." rowspan="1" colspan="1">61</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">≥3.5</td>
                        <td align="char" char="." rowspan="1" colspan="1">68</td>
                        <td align="char" char="." rowspan="1" colspan="1">84</td>
                        <td align="char" char="." rowspan="1" colspan="1">88</td>
                        <td align="char" char="." rowspan="1" colspan="1">61</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">≥3.7</td>
                        <td align="char" char="." rowspan="1" colspan="1">57</td>
                        <td align="char" char="." rowspan="1" colspan="1">86</td>
                        <td align="char" char="." rowspan="1" colspan="1">84</td>
                        <td align="char" char="." rowspan="1" colspan="1">59</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">T1; 0.72 (95% CI: 0.61-0.82) (ms)</td>
                        <td align="center" rowspan="1" colspan="1">≥750</td>
                        <td align="char" char="." rowspan="1" colspan="1">100</td>
                        <td align="char" char="." rowspan="1" colspan="1">28</td>
                        <td align="char" char="." rowspan="1" colspan="1">100</td>
                        <td align="char" char="." rowspan="1" colspan="1">34</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">≥800</td>
                        <td align="char" char="." rowspan="1" colspan="1">82</td>
                        <td align="char" char="." rowspan="1" colspan="1">41</td>
                        <td align="char" char="." rowspan="1" colspan="1">86</td>
                        <td align="char" char="." rowspan="1" colspan="1">34</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">≥850</td>
                        <td align="char" char="." rowspan="1" colspan="1">75</td>
                        <td align="char" char="." rowspan="1" colspan="1">63</td>
                        <td align="char" char="." rowspan="1" colspan="1">87</td>
                        <td align="char" char="." rowspan="1" colspan="1">43</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">≥900</td>
                        <td align="char" char="." rowspan="1" colspan="1">54</td>
                        <td align="char" char="." rowspan="1" colspan="1">71</td>
                        <td align="char" char="." rowspan="1" colspan="1">81</td>
                        <td align="char" char="." rowspan="1" colspan="1">41</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1">≥950</td>
                        <td align="char" char="." rowspan="1" colspan="1">46</td>
                        <td align="char" char="." rowspan="1" colspan="1">80</td>
                        <td align="char" char="." rowspan="1" colspan="1">80</td>
                        <td align="char" char="." rowspan="1" colspan="1">46</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn fn-type="abbr">
                      <p>Abbreviations: LS, liver stiffness; NPV, negative predictive value; PPV, positive predictive value.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>When evaluated in those with and without diabetes, the diagnostic performance of the imaging parameters was similar, although the CIs for the AUC were larger due to the decrease in sample sizes of the 2 groups.</p>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>DISCUSSION</title>
              <p>In this prospective study, we directly compared LS, PDFF, T1, and 4 multiparametric models of MRI/MRE parameters for the detection of NASH and at-risk NASH.</p>
              <p>To our knowledge, this is the head-to-head comparison study on the performance of LS, PDFF, and T1 for NASH and at-risk NASH. MRE-assessed LS is a well-established most accurate imaging biomarker for diagnosing clinically significant fibrosis.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> In this analysis, LS alone showed the highest diagnostic accuracy in identifying at-risk NASH [AUC: 0.89 (0.82, 0.95)]. The inferior performance of the models with additional parameters to LS is likely due to collinearity or nonlinear relationship between steatosis and NAFLD severity,<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup> described as “burnt-out” NASH (Supplemental Figure S3, <ext-link xlink:href="http://links.lww.com/HEP/H132" ext-link-type="uri">http://links.lww.com/HEP/H132</ext-link>). In contrast, the LS is known to monotonically increase with fibrosis,<sup><xref rid="R23" ref-type="bibr">23</xref></sup> inflammation,<sup><xref rid="R24" ref-type="bibr">24</xref></sup> and ballooning,<sup><xref rid="R25" ref-type="bibr">25</xref></sup> which are all hallmark histopathologic features of at-risk NASH.</p>
              <p>Consistent with previous studies, T1 correlated with hepatic steatosis and fibrosis.<sup><xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup> Compared with LS or PDFF, however, T1 was inferior in diagnosing patients with at-risk NASH or NASH, respectively. A recent meta-analysis of multicenter pooled data assessed the clinical utility of PDFF and cT1, for identifying patients with NASH and at-risk NASH.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> The diagnostic performance for identifying NASH was similar (AUC<sub>cT1</sub>: 0.78 vs AUC<sub>PDFF</sub>: 0.78). For at-risk NASH diagnosis, cT1 outperformed PDFF in the pooled analysis (AUC<sub>cT1</sub>: 0.78 vs AUC<sub>PDFF</sub>: 0.69, <italic toggle="yes">p</italic> &lt; 0.001), whereas in individual patient data meta-analysis, the performance of cT1 was inferior (AUC<sub>cT1</sub>: 0.73 vs AUC<sub>PDFF</sub>: 0.69). Notably, there was significant heterogeneity across sites, with one site (n = 26) reporting AUC 0.57 (0.27, 0.87) for cT1 in diagnosing at-risk NASH. Technically, the single-point saturation-recovery acquisition method has been shown to provide more accurate and robust T1 measurements than the MOLLI method (cT1)<sup><xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref></sup> (detailed information for T1 and cT1 could be found in Supplemental Material S4, <ext-link xlink:href="http://links.lww.com/HEP/H132" ext-link-type="uri">http://links.lww.com/HEP/H132</ext-link>). Both cT1 and T1 measure a mixed signal from water and fat in the liver,<sup><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup> and have a potential bias from the partial volume effect of steatosis.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> Consequently, T1 is significantly associated with PDFF measurements in NAFLD/NASH.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> Therefore, the inferior performance of T1 in diagnosing NASH and at-risk NASH observed in this study is likely due to signal confounders and collinearity with the other biomarkers.</p>
              <p>Cost is an important consideration in the application of imaging-based biomarkers. An MRI examination consisting of MRE alone or MRE with PDFF is much less expensive than the procedure for obtaining cT1 and PDFF. To obtain a measurement of liver cT1, an MRI procedure is performed using a proprietary protocol and the data must be sent for external processing for an extra cost. According to the US Centers for Medicaid and Medicare Services, the relevant charges are ~$350 (MRI abdomen without contrast, CPT code 74181) and $950 (quantitative MR tissue analysis, CPT code 0648T), for a total of ~$1300 (which would include a PDFF measurement). The Centers for Medicaid and Medicare Services charge for MRE is ~$240 (CPT code 76391). The acquisition for PDFF requires only a single breath-hold and could be included in the MRE examination at no additional charge. Even if it is charged as an “abdomen without contrast” (CPT code 74181), the total Centers for Medicaid and Medicare Services charge for MRE + PDFF would be less than half that for cT1 + PDFF.</p>
              <p>Similarly, cost-effectiveness studies with nonimaging biomarkers are warranted. Many studies demonstrated that MRE-assessed LS is superior in stratifying at-risk NASH compared with NIS4 [AUC: 0.80 (0.77, 0.84)],<sup><xref rid="R33" ref-type="bibr">33</xref></sup> FAST (FibroScan-Aspartate aminotransferase) score [AUC: 0.80 (0.76, 0.85)],<sup><xref rid="R34" ref-type="bibr">34</xref></sup> and LAD-NASH (predictive model with US markers of liver stiffness, attenuation coefficient, and dispersion slope) score [AUC: 0.86 (0.79, 0.93)].<sup><xref rid="R35" ref-type="bibr">35</xref></sup>
</p>
              <p>There are several strengths of this study. As the head-to-head comparison study, the number of paired examinations (N = 104) is sufficiently large. The post hoc power analysis for group comparisons is over 89%. Furthermore, for all 104 examinations with paired concurrent biopsy, the median time interval is very short [1 d (1, 7)], which provided reliable histology information. Centralized data collection and processing avoided interobserver bias in histologic interpretation. Several limitations are worth noting. First, this is a single-center study, without external validation. To mitigate this limitation, the model performance was calculated using leave-one-out cross-validation methods. Second, there were 15 participants who underwent 2 examinations/biopsies 1 year apart. To mitigate potential bias related to measurements in the same participant, concordance analysis with a robust variance estimator was performed to correct the within-subject correlation. The diagnostic performance of models in 89 participants without repeated examinations showed similar results as the original analysis (Supplemental Figure and Table S5, Supplemental Digital Content 1, <ext-link xlink:href="http://links.lww.com/HEP/H132" ext-link-type="uri">http://links.lww.com/HEP/H132</ext-link>). Third, the sample size is relatively small, with only 28 (27%) out of 104 examinations having at-risk NASH by histology, when most patients had mild liver disease with low inflammation and ballooning grade. Nevertheless, this reflects the real-world prevalence of at-risk NASH and enables the generalization of these results, including the positive predictive value and NPV for clinical practice.<sup><xref rid="R36" ref-type="bibr">36</xref></sup> These results should be validated in multicenter cohorts with larger sample sizes.</p>
              <p>In conclusion, this study demonstrates that among the imaging biomarkers evaluated, MRE-assessed LS has the highest accuracy for identifying at-risk NASH. Therefore, MRE is the most accurate test to identify patients with NASH and stage 2–3 fibrosis or cirrhosis who may qualify for drug therapies in clinical trials and practice once approved.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <fig id="s001" position="anchor">
                <media xlink:href="hep-78-1200-s001.docx"/>
              </fig>
            </sec>
          </body>
          <back>
            <ack>
              <sec sec-type="COI-statement">
                <title>AUTHOR CONTRIBUTIONS</title>
                <p>Study design, database creation, and data acquisition: Jiahui Li, Xin Lu, and Zheng Zhu. Manuscript preparation: Jiahui Li, Xin Lu, Alina M. Allen, and Meng Yin. Statistical analysis: Jiahui Li and Kyle J. Kalutkiewicz. Statistical review: Terry M. Therneau. Critical revision of the manuscript: Jiahui Li, Terry M. Therneau, Richard L. Ehman, Alina M. Allen, and Meng Yin. Imaging review: Safa Hoodeshenas, Sudhakar K. Venkatesh, and Taofic Mounajjed. Technical/material support: Yi Sui, Kevin J. Glaser, Armando Manduca, Sudhakar K. Venkatesh, Vijay H. Shah, Richard L. Ehman, Alina M. Allen, and Meng Yin. Study concept and design, database creation, funding obtainment, and study supervision: Vijay H. Shah, Richard L. Ehman, Alina M. Allen, and Meng Yin.</p>
              </sec>
              <sec>
                <title>FUNDING INFORMATION</title>
                <p>This work has been supported by grant funding from the National Institutes of Health (K23 DK115594, P30 DK084567, R01 AA021171, R37 EB001981, R01 EB017197), the US Department of Defense (W81XWH-19-1-0583-01), and the Mayo Clinic.</p>
              </sec>
              <sec sec-type="COI-statement">
                <title>CONFLICTS OF INTEREST</title>
                <p>Kyle J. Kalutkiewicz is employed by and consults for Resoundant, Inc. Kevin J. Glaser owns stock in and intellectual property rights with Resoundant, Inc. Armando Manduca owns stock in Resoundant, Inc. Richard L. Ehman owns stock in, owns intellectual property rights with, and received grants from Resoundant, Inc. Alina M. Allen consults for, advises, and received grants from Novo Nordisk. She received grants from Pfizer and Target Pharma. Meng Yin owns stock in and intellectual property rights with Resoundant, Inc. The remaining authors have no conflicts to report.</p>
              </sec>
            </ack>
            <fn-group>
              <fn fn-type="abbr">
                <p><bold>Abbreviations</bold>: BMI, body mass index; cT1, corrected T1; LS, liver stiffness; MRE, magnetic resonance elastography; NPV, negative predictive value; PDFF, proton density fat fraction; PPV, positive predictive value; ROI, regions of interest.</p>
              </fn>
              <fn fn-type="other">
                <p>Jiahui Li and Xin Lu are co-first authors.</p>
              </fn>
              <fn fn-type="supplementary-material">
                <p>Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, <ext-link xlink:href="http://www.hepjournal.com" ext-link-type="uri">www.hepjournal.com</ext-link>.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paik</surname><given-names>JM</given-names></name><name><surname>Golabi</surname><given-names>P</given-names></name><name><surname>Younossi</surname><given-names>Y</given-names></name><name><surname>Srishord</surname><given-names>M</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Younossi</surname><given-names>ZM</given-names></name></person-group>. <article-title>The growing burden of disability related to nonalcoholic fatty liver disease: Data from the global burden of disease 2007–2017</article-title>. <source>Hepatol Commun</source>. <year>2020</year>;<volume>4</volume>:<fpage>1769</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">33305148</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sepanlou</surname><given-names>SG</given-names></name><name><surname>Safiri</surname><given-names>S</given-names></name><name><surname>Bisignano</surname><given-names>C</given-names></name><name><surname>Ikuta</surname><given-names>KS</given-names></name><name><surname>Merat</surname><given-names>S</given-names></name><name><surname>Saberifiroozi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017</article-title>. <source>Lancet Gastroenterol Hepatol</source>. <year>2020</year>;<volume>5</volume>:<fpage>245</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">31981519</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>TG</given-names></name><name><surname>Roelstraete</surname><given-names>B</given-names></name><name><surname>Khalili</surname><given-names>H</given-names></name><name><surname>Hagström</surname><given-names>H</given-names></name><name><surname>Ludvigsson</surname><given-names>JF</given-names></name></person-group>. <article-title>Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort</article-title>. <source>Gut</source>. <year>2021</year>;<volume>70</volume>:<fpage>1375</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">33037056</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleiner</surname><given-names>DE</given-names></name><name><surname>Brunt</surname><given-names>EM</given-names></name><name><surname>Wilson</surname><given-names>LA</given-names></name><name><surname>Behling</surname><given-names>C</given-names></name><name><surname>Guy</surname><given-names>C</given-names></name><name><surname>Contos</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Association of histologic disease activity with progression of nonalcoholic fatty liver disease</article-title>. <source>JAMA Netw Open</source>. <year>2019</year>;<volume>2</volume>:<fpage>e1912565</fpage>.<pub-id pub-id-type="pmid">31584681</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowe</surname><given-names>IA</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name></person-group>. <article-title>The diagnosis of nonalcoholic fatty liver disease should carry important prognostic information</article-title>. <source>Nat Rev Gastroenterol Hepatol</source>. <year>2019</year>;<volume>16</volume>:<fpage>449</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">31197261</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dulai</surname><given-names>PS</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Soni</surname><given-names>M</given-names></name><name><surname>Prokop</surname><given-names>LJ</given-names></name><name><surname>Younossi</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis</article-title>. <source>Hepatology</source>. <year>2017</year>;<volume>65</volume>:<fpage>1557</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">28130788</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekstedt</surname><given-names>M</given-names></name><name><surname>Hagström</surname><given-names>H</given-names></name><name><surname>Nasr</surname><given-names>P</given-names></name><name><surname>Fredrikson</surname><given-names>M</given-names></name><name><surname>Stål</surname><given-names>P</given-names></name><name><surname>Kechagias</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up</article-title>. <source>Hepatology</source>. <year>2015</year>;<volume>61</volume>:<fpage>1547</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">25125077</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Venkatesh</surname><given-names>SK</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Miller</surname><given-names>FH</given-names></name><name><surname>Motosugi</surname><given-names>U</given-names></name><name><surname>Low</surname><given-names>RN</given-names></name><etal/></person-group>. <article-title>Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2015</year>;<volume>13</volume>:<fpage>440</fpage>–<lpage>51 e446</lpage>.<pub-id pub-id-type="pmid">25305349</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Idilman</surname><given-names>IS</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>M</given-names></name><name><surname>Venkatesh</surname><given-names>SK</given-names></name></person-group>. <article-title>MR elastography of liver: current status and future perspectives</article-title>. <source>Abdom Radiol (NY)</source>. <year>2020</year>;<volume>45</volume>:<fpage>3444</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">32705312</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvaraj</surname><given-names>EA</given-names></name><name><surname>Mózes</surname><given-names>FE</given-names></name><name><surname>Jayaswal</surname><given-names>ANA</given-names></name><name><surname>Zafarmand</surname><given-names>MH</given-names></name><name><surname>Vali</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis</article-title>. <source>J Hepatol</source>. <year>2021</year>;<volume>75</volume>:<fpage>770</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="pmid">33991635</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dzyubak</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Mara</surname><given-names>KC</given-names></name><name><surname>Therneau</surname><given-names>TM</given-names></name><name><surname>Venkatesh</surname><given-names>SK</given-names></name><etal/></person-group>. <article-title>Automated Analysis of multiparametric magnetic resonance imaging/magnetic resonance elastography exams for prediction of nonalcoholic steatohepatitis</article-title>. <source>J Magn Reson Imaging</source>. <year>2021</year>;<volume>54</volume>:<fpage>122</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">33586159</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noureddin</surname><given-names>M</given-names></name><name><surname>Lam</surname><given-names>J</given-names></name><name><surname>Peterson</surname><given-names>MR</given-names></name><name><surname>Middleton</surname><given-names>M</given-names></name><name><surname>Hamilton</surname><given-names>G</given-names></name><name><surname>Le</surname><given-names>TA</given-names></name><etal/></person-group>. <article-title>Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials</article-title>. <source>Hepatology</source>. <year>2013</year>;<volume>58</volume>:<fpage>1930</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">23696515</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Troelstra</surname><given-names>MA</given-names></name><name><surname>Witjes</surname><given-names>JJ</given-names></name><name><surname>van Dijk</surname><given-names>AM</given-names></name><name><surname>Mak</surname><given-names>AL</given-names></name><name><surname>Gurney-Champion</surname><given-names>O</given-names></name><name><surname>Runge</surname><given-names>JH</given-names></name><etal/></person-group>. <article-title>Assessment of imaging modalities against liver biopsy in nonalcoholic fatty liver disease: The Amsterdam NAFLD-NASH cohort</article-title>. <source>J Magn Reson Imaging</source>. <year>2021</year>;<volume>54</volume>:<fpage>1937</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">33991378</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>M</given-names></name><name><surname>Imajo</surname><given-names>K</given-names></name><name><surname>Nakajima</surname><given-names>A</given-names></name><name><surname>Fallowfield</surname><given-names>JA</given-names></name><name><surname>Hirschfield</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Clinical utility of MRI biomarkers for identifying NASH patients at high risk of progression: a multicenter pooled data and meta-analysis.</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2022</year>;<volume>20</volume>:<fpage>2451</fpage>–<lpage>2461.e3</lpage>.<pub-id pub-id-type="pmid">34626833</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pournik</surname><given-names>O</given-names></name><name><surname>Alavian</surname><given-names>SM</given-names></name><name><surname>Ghalichi</surname><given-names>L</given-names></name><name><surname>Seifizarei</surname><given-names>B</given-names></name><name><surname>Mehrnoush</surname><given-names>L</given-names></name><name><surname>Aslani</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Inter-observer and intra-observer agreement in pathological evaluation of non-alcoholic fatty liver disease suspected liver biopsies</article-title>. <source>Hepat Mon</source>. <year>2014</year>;<volume>14</volume>:<fpage>e15167</fpage>.<pub-id pub-id-type="pmid">24497882</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><collab>ClinicalTrails.gov</collab>. <comment>Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram. 2015. Accessed May 11, 2023.</comment><ext-link xlink:href="https://ClinicalTrials.gov/show/NCT02565446" ext-link-type="uri">https://ClinicalTrials.gov/show/NCT02565446</ext-link>.</mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manduca</surname><given-names>A</given-names></name><name><surname>Bayly</surname><given-names>PJ</given-names></name><name><surname>Ehman</surname><given-names>RL</given-names></name><name><surname>Kolipaka</surname><given-names>A</given-names></name><name><surname>Royston</surname><given-names>TJ</given-names></name><name><surname>Sack</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>MR elastography: Principles, guidelines, and terminology</article-title>. <source>Magn Reson Med</source>. <year>2021</year>;<volume>85</volume>:<fpage>2377</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">33296103</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleiner</surname><given-names>DE</given-names></name><name><surname>Brunt</surname><given-names>EM</given-names></name><name><surname>Van Natta</surname><given-names>M</given-names></name><name><surname>Behling</surname><given-names>C</given-names></name><name><surname>Contos</surname><given-names>MJ</given-names></name><name><surname>Cummings</surname><given-names>OW</given-names></name><etal/></person-group>. <article-title>Design and validation of a histological scoring system for nonalcoholic fatty liver disease</article-title>. <source>Hepatology</source>. <year>2005</year>;<volume>41</volume>:<fpage>1313</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">15915461</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Petrick</surname><given-names>NA</given-names></name><name><surname>Gallas</surname><given-names>BD</given-names></name></person-group>. <article-title>Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach</article-title>. <source>Stat Med</source>. <year>2015</year>;<volume>34</volume>:<fpage>685</fpage>–<lpage>703</lpage>.<pub-id pub-id-type="pmid">25399736</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YN</given-names></name><name><surname>Fowler</surname><given-names>KJ</given-names></name><name><surname>Boehringer</surname><given-names>AS</given-names></name><name><surname>Montes</surname><given-names>V</given-names></name><name><surname>Schlein</surname><given-names>AN</given-names></name><name><surname>Covarrubias</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease</article-title>. <source>Eur Radiol</source>. <year>2022</year>;<volume>32</volume>:<fpage>2457</fpage>–<lpage>2469</lpage>.<pub-id pub-id-type="pmid">34854929</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wildman-Tobriner</surname><given-names>B</given-names></name><name><surname>Middleton</surname><given-names>MM</given-names></name><name><surname>Moylan</surname><given-names>CA</given-names></name><name><surname>Rossi</surname><given-names>S</given-names></name><name><surname>Flores</surname><given-names>O</given-names></name><name><surname>Chang</surname><given-names>ZA</given-names></name><etal/></person-group>. <article-title>Association between magnetic resonance imaging-proton density fat fraction and liver histology features in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis</article-title>. <source>Gastroenterology</source>. <year>2018</year>;<volume>155</volume>:<fpage>1428</fpage>–<lpage>35.e1422</lpage>.<pub-id pub-id-type="pmid">30031769</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>MD</given-names></name><name><surname>Fernandes</surname><given-names>C</given-names></name><name><surname>Mouchti</surname><given-names>S</given-names></name><name><surname>Fallowfield</surname><given-names>JA</given-names></name><name><surname>Hirschfield</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis</article-title>. <source>Front Endocrinol</source>. <year>2021</year>;<volume>11</volume>:<fpage>575843</fpage>.</mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Allen</surname><given-names>AM</given-names></name><name><surname>Therneau</surname><given-names>TM</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Hoodeshenas</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis</article-title>. <source>Eur Radiol</source>. <year>2022</year>;<volume>32</volume>:<fpage>950</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">34432123</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Allen</surname><given-names>AM</given-names></name><name><surname>Shah</surname><given-names>VH</given-names></name><name><surname>Manduca</surname><given-names>A</given-names></name><name><surname>Ehman</surname><given-names>RL</given-names></name><name><surname>Yin</surname><given-names>M</given-names></name></person-group>. <article-title>NAFLD MR Imaging Research Group. Longitudinal changes in MR elastography-based biomarkers in obese patients treated with bariatric surgery</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2023</year>;<volume>21</volume>:<fpage>220</fpage>–<lpage>222.e3</lpage>.<pub-id pub-id-type="pmid">34757198</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imajo</surname><given-names>K</given-names></name><name><surname>Tetlow</surname><given-names>L</given-names></name><name><surname>Dennis</surname><given-names>A</given-names></name><name><surname>Shumbayawonda</surname><given-names>E</given-names></name><name><surname>Mouchti</surname><given-names>S</given-names></name><name><surname>Kendall</surname><given-names>TJ</given-names></name><etal/></person-group>. <article-title>Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort</article-title>. <source>World J Gastroenterol</source>. <year>2021</year>;<volume>27</volume>:<fpage>609</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">33642832</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>JH</given-names></name><name><surname>Yu</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Kang</surname><given-names>SH</given-names></name><name><surname>Huh</surname><given-names>JH</given-names></name><name><surname>Chang</surname><given-names>JS</given-names></name><etal/></person-group>. <article-title>Effect of hepatic steatosis on native T1 mapping of 3T magnetic resonance imaging in the assessment of T1 values for patients with non-alcoholic fatty liver disease</article-title>. <source>Magn Reson Imaging</source>. <year>2021</year>;<volume>80</volume>:<fpage>1</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">33798658</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>N</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Assessment of liver fibrosis by variable flip angle T1 mapping at 3.0T</article-title>. <source>J Magn Reson Imaging</source>. <year>2016</year>;<volume>43</volume>:<fpage>698</fpage>–<lpage>703</lpage>.<pub-id pub-id-type="pmid">26267123</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slavin</surname><given-names>GS</given-names></name><name><surname>Stainsby</surname><given-names>JA</given-names></name></person-group>. <article-title>True T1 mapping with SMART(1)Map (saturation method using adaptive recovery times for cardiac T(1) mapping): a comparison with MOLLI</article-title>. <source>J Cardiovasc Magn Reson</source>. <year>2013</year>;<volume>15</volume>(<issue>suppl 1</issue>):<fpage>P3</fpage>.</mixed-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stainsby</surname><given-names>JA</given-names></name><name><surname>Slavin</surname><given-names>GS</given-names></name></person-group>. <article-title>Comparing the accuracy and precision of SMART1Map, SASHA and MOLLI</article-title>. <source>J Cardiovasc Magn Reson</source>. <year>2014</year>;<volume>16</volume>:<fpage>P11</fpage>.</mixed-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erden</surname><given-names>A</given-names></name><name><surname>Kuru Öz</surname><given-names>D</given-names></name><name><surname>Peker</surname><given-names>E</given-names></name><name><surname>Kul</surname><given-names>M</given-names></name><name><surname>Özalp Ateş</surname><given-names>FS</given-names></name><name><surname>Erden</surname><given-names>İ</given-names></name><etal/></person-group>. <article-title>MRI quantification techniques in fatty liver: the diagnostic performance of hepatic T1, T2, and stiffness measurements in relation to the proton density fat fraction</article-title>. <source>Diagn Interv Radiol</source>. <year>2021</year>;<volume>27</volume>:<fpage>7</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">33290237</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mojtahed</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>CJ</given-names></name><name><surname>Herlihy</surname><given-names>AH</given-names></name><name><surname>Kin</surname><given-names>S</given-names></name><name><surname>Wilman</surname><given-names>HR</given-names></name><name><surname>McKay</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Reference range of liver corrected T1 values in a population at low risk for fatty liver disease—a UK Biobank sub-study, with an appendix of interesting cases</article-title>. <source>Abdominal Radiol</source>. <year>2019</year>;<volume>44</volume>:<fpage>72</fpage>–<lpage>84</lpage>.</mixed-citation>
              </ref>
              <ref id="R32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellman</surname><given-names>P</given-names></name><name><surname>Bandettini</surname><given-names>WP</given-names></name><name><surname>Mancini</surname><given-names>C</given-names></name><name><surname>Hammer-Hansen</surname><given-names>S</given-names></name><name><surname>Hansen</surname><given-names>MS</given-names></name><name><surname>Arai</surname><given-names>AE</given-names></name></person-group>. <article-title>Characterization of myocardial T1-mapping bias caused by intramyocardial fat in inversion recovery and saturation recovery techniques</article-title>. <source>J Cardiovasc Magn Reson</source>. <year>2015</year>;<volume>17</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">25958014</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>SA</given-names></name><name><surname>Ratziu</surname><given-names>V</given-names></name><name><surname>Boursier</surname><given-names>J</given-names></name><name><surname>Francque</surname><given-names>S</given-names></name><name><surname>Bedossa</surname><given-names>P</given-names></name><name><surname>Majd</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study</article-title>. <source>Lancet Gastroenterol Hepatol</source>. <year>2020</year>;<volume>5</volume>:<fpage>970</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="pmid">32763196</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newsome</surname><given-names>PN</given-names></name><name><surname>Sasso</surname><given-names>M</given-names></name><name><surname>Deeks</surname><given-names>JJ</given-names></name><name><surname>Paredes</surname><given-names>A</given-names></name><name><surname>Boursier</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>WK</given-names></name><etal/></person-group>. <article-title>FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study</article-title>. <source>Lancet Gastroenterol Hepatol</source>. <year>2020</year>;<volume>5</volume>:<fpage>362</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">32027858</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugimoto</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Yu</surname><given-names>SJ</given-names></name><name><surname>Moriyasu</surname><given-names>F</given-names></name><name><surname>Sakamaki</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Multiparametric US for identifying patients with high-risk NASH: A derivation and validation study</article-title>. <source>Radiology</source>. <year>2021</year>;<volume>301</volume>:<fpage>625</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="pmid">34519576</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perumpail</surname><given-names>BJ</given-names></name><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>Yoo</surname><given-names>ER</given-names></name><name><surname>Cholankeril</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name></person-group>. <article-title>Clinical epidemiology and disease burden of nonalcoholic fatty liver disease</article-title>. <source>World J Gastroenterol</source>. <year>2017</year>;<volume>23</volume>:<fpage>8263</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">29307986</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
